勃起功能障礙（ED）市場規模、佔有率和成長分析（按治療方法、最終用戶和地區分類）—2026-2033年產業預測

全球勃起功能障礙（ED）市場規模預計在 2024 年達到 27.2 億美元，從 2025 年的 29.6 億美元成長到 2033 年的 58.1 億美元，在預測期（2026-2033 年）內複合年成長率為 8.8%。

勃起功能障礙，即在性生活中無法達到或維持令人滿意的陰莖勃起，是男性性健康的常見問題，嚴重影響其身心健康。其病因主要分為兩類：心理因素和生理因素，後者包括高血壓、高膽固醇、肥胖、糖尿病和吸菸等生活型態因素。由於該疾病盛行率不斷上升，勃起功能障礙治療市場持續成長。預計市場參與企業將對現有治療方法有更深入的了解。然而，陰莖植入的高昂費用是市場擴張面臨的一大挑戰，這可能會阻礙許多男性尋求有效的解決方案。

全球勃起功能障礙市場促進因素

全球勃起功能障礙市場的主要驅動力是糖尿病、肥胖症和心血管疾病的日益普遍，而這些疾病又與不健康的生活方式密切相關。隨著老齡化，這些健康問題愈發突出，並導致勃起功能障礙的發生。尤其在許多開發中國家，年輕人的壓力水平不斷上升，蒸餾、即食食品、酒精和菸草的消費量也在增加。這些生活習慣會對整體健康產生負面影響，並增加勃起功能障礙的風險。此外，人口老化加劇了這個問題，進一步推動了全球對勃起功能障礙治療的需求。

限制全球勃起功能障礙藥物市場的因素

全球勃起功能障礙治療市場面臨許多挑戰，包括銷售量有限，尤其是中低收入國家。這主要是由於人們對現有治療方法的認知度低，以及經濟拮据導致購買力不足。此外，社會上不願將此類治療方法融入日常生活也加劇了這個問題。市場成長緩慢也與勃起功能障礙藥物的副作用有關，例如頭痛、消化器官系統問題、臉部潮紅、鼻塞、視力障礙、頭暈、腹瀉和皮疹。這些副作用可能會阻礙潛在使用者尋求必要的治療。

全球勃起功能障礙治療市場趨勢

全球勃起功能障礙藥物市場正經歷顯著的成長，這主要得益於Sildenafil（通用名：威而鋼）的有效性和廣泛應用。該藥物已成為治療勃起功能障礙的第一線藥物，許多使用者報告指出勃起功能已改善。隨著人們對性健康問題的認知不斷提高，以及圍繞勃起功能障礙的社會污名逐漸消退，越來越多的男性開始尋求治療方案。此外，對潛在新治療方法的持續研究和治療方法的進步也推動了市場成長。勃起功能障礙盛行率的不斷上升進一步刺激了市場需求，使其成為全球醫療保健領域一個充滿活力且不斷發展的領域。

目錄

介紹

• 調查目標
• 調查範圍
• 定義

調查方法

• 資訊收集
• 二手資料和一手資料方法
• 市場規模預測
• 市場假設與限制

執行摘要

• 全球市場展望
• 供需趨勢分析
• 細分市場機會分析

市場動態與展望

• 市場規模
• 市場動態
  • 促進因素和機遇
  • 限制與挑戰
• 波特分析

關鍵市場考察

• 關鍵成功因素
• 競爭程度
• 關鍵投資機會
• 市場生態系統
• 市場吸引力指數（2025）
• PESTEL 分析
• 總體經濟指標
• 價值鏈分析
• 定價分析

全球勃起功能障礙（ED）市場規模（按治療方法和複合年成長率分類）（2026-2033 年）

• 藥物
• Sildenafil
• 他達拉非
• 伐地那非
• 阿伐那菲爾
• 其他
• 陰莖植入
• 陰莖幫浦
• 其他

全球勃起功能障礙（ED）市場規模（按最終用戶分類）及複合年成長率（2026-2033 年）

• 醫院和診所
• 門診手術中心
• 藥局
• 其他

全球勃起功能障礙（ED）市場規模及複合年成長率（2026-2033）

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲地區
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 亞太其他地區
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地區
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲地區

競爭資訊

• 前五大公司對比
• 主要企業的市場定位（2025 年）
• 主要市場參與者所採取的策略
• 近期市場趨勢
• 公司市佔率分析（2025 年）
• 主要企業公司簡介
  • 公司詳情
  • 產品系列分析
  • 依業務板塊進行公司股票分析
  • 2023-2025年營收年比比較

主要企業簡介

• Pfizer（US）
• Eli Lilly and Company（US）
• Bayer AG（Germany）
• Takeda Pharmaceutical Company（Japan）
• Mylan（US）（Now Viatris）
• Viatris（US）
• Teva Pharmaceutical Industries（Israel）
• Sun Pharmaceutical Industries（India）
• Cipla（India）
• Aurobindo Pharma（India）
• Lupin Limited（India）
• Dr. Reddy's Laboratories（India）
• Sandoz（Switzerland）
• Novartis（Switzerland）
• Abbott Laboratories（US）
• Sanofi（France）
• GlaxoSmithKline（GSK）（UK）
• Johnson & Johnson（US）
• Boston Scientific（US）
• Coloplast（Denmark）

結論與建議

Global Erectile Dysfunction Market size was valued at USD 2.72 Billion in 2024 and is poised to grow from USD 2.96 Billion in 2025 to USD 5.81 Billion by 2033, growing at a CAGR of 8.8% during the forecast period (2026-2033).

Erectile dysfunction, characterized by the inability to achieve or maintain an adequate penile erection during sexual activity, is a prevalent issue in male sexual health that significantly impacts both physical and mental well-being. It arises from two primary factors: psychological and physiological, with the latter including conditions such as high blood pressure, high cholesterol, obesity, diabetes, and lifestyle choices like smoking. The market for erectile dysfunction treatments is witnessing growth driven by an increase in affected individuals. Market participants are expected to enhance their understanding of available treatments. However, a notable challenge to market expansion is the high cost associated with penile implants, which may hinder accessibility for many seeking effective solutions.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Erectile Dysfunction market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Erectile Dysfunction Market Segments Analysis

Global Erectile Dysfunction Market is segmented by Treatment Type, End User and region. Based on Treatment Type, the market is segmented into Drugs, Sildenafil, Tadalafil, Vardenafil, Avanafil, Others, Penile Implants, Penis Pumps and Others. Based on End User, the market is segmented into Hospitals & Clinics, Ambulatory Surgery Centers, Pharmacies and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Erectile Dysfunction Market

The global erectile dysfunction market is significantly driven by the increasing prevalence of diabetes, obesity, and cardiovascular diseases, which are closely linked to unhealthy lifestyle choices. As individuals age, these health challenges become more pronounced, contributing to the incidence of erectile dysfunction. Particularly in many developing countries, younger populations experience heightened stress levels, leading to a surge in the consumption of fast food, ready-to-eat meals, alcohol, and tobacco. These lifestyle habits negatively impact overall health, thereby elevating the risk of erectile dysfunction. Furthermore, the rising senior population further exacerbates this issue, fueling demand for erectile dysfunction treatments worldwide.

Restraints in the Global Erectile Dysfunction Market

The global erectile dysfunction market faces significant challenges, particularly in low- and middle-income countries where sales are limited. This is largely due to a lack of awareness about available treatments, combined with economic constraints that hinder purchasing capabilities. Furthermore, societal reluctance to integrate such options into daily life exacerbates the situation. Additionally, the slow market growth can be linked to the adverse effects associated with erectile dysfunction medications, including headaches, digestive issues, facial flushing, nasal congestion, visual disturbances, dizziness, diarrhea, and skin rashes; these side effects can deter potential users from seeking necessary treatment.

Market Trends of the Global Erectile Dysfunction Market

The Global Erectile Dysfunction market is experiencing a significant upward trajectory, primarily driven by the efficacy and popularity of sildenafil, commonly known as Viagra. This medication has established itself as the first-line treatment for erectile dysfunction, with a substantial portion of users reporting improved erection quality. As awareness of sexual health issues increases and societal stigmas around discussing erectile dysfunction diminish, more men are seeking treatment options. Additionally, ongoing research into potential new therapies and advancements in treatment methods contribute to the market's growth. The rising prevalence of erectile dysfunction further fuels demand, making this an evolving and dynamic sector within the global healthcare landscape.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2025
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis

Global Erectile Dysfunction Market Size by Treatment Type & CAGR (2026-2033)

• Market Overview
• Drugs
• Sildenafil
• Tadalafil
• Vardenafil
• Avanafil
• Others
• Penile Implants
• Penis Pumps
• Others

Global Erectile Dysfunction Market Size by End User & CAGR (2026-2033)

• Market Overview
• Hospitals & Clinics
• Ambulatory Surgery Centers
• Pharmacies
• Others

Global Erectile Dysfunction Market Size & CAGR (2026-2033)

• North America (Treatment Type, End User)
  • US
  • Canada
• Europe (Treatment Type, End User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Treatment Type, End User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Treatment Type, End User)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Treatment Type, End User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Pfizer (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Mylan (US) (Now Viatris)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Viatris (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries (Israel)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sun Pharmaceutical Industries (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cipla (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Aurobindo Pharma (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Lupin Limited (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Dr. Reddy's Laboratories (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sandoz (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Abbott Laboratories (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline (GSK) (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Boston Scientific (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Coloplast (Denmark)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations